These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 19117357)
21. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Zesiewicz TA; Elble R; Louis ED; Hauser RA; Sullivan KL; Dewey RB; Ondo WG; Gronseth GS; Weiner WJ; Neurology; 2005 Jun; 64(12):2008-20. PubMed ID: 15972843 [TBL] [Abstract][Full Text] [Related]
22. Zonisamide in patients with essential tremor and Parkinson's disease. Bermejo PE Mov Disord; 2007 Oct; 22(14):2137-8. PubMed ID: 17853481 [No Abstract] [Full Text] [Related]
23. [Zonisamide in refractory essential tremor]. Bermejo PE; Ruiz-Huete C; Dorado R; Anciones B Rev Neurol; 2008 Feb 1-15; 46(3):139-42. PubMed ID: 18297619 [TBL] [Abstract][Full Text] [Related]
24. A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor. Santos de Alencar S; Crippa JAS; Brito MCM; Pimentel ÂV; Cecilio Hallak JE; Tumas V Parkinsonism Relat Disord; 2021 Feb; 83():37-40. PubMed ID: 33465546 [TBL] [Abstract][Full Text] [Related]
25. Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics. Samotus O; Kumar N; Rizek P; Jog M Can J Neurol Sci; 2018 Jan; 45(1):11-22. PubMed ID: 29157315 [TBL] [Abstract][Full Text] [Related]
26. Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. Samotus O; Lee J; Jog M PLoS One; 2017; 12(6):e0178670. PubMed ID: 28586370 [TBL] [Abstract][Full Text] [Related]
27. The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. Feys P; D'hooghe MB; Nagels G; Helsen WF Mult Scler; 2009 Mar; 15(3):371-8. PubMed ID: 19168602 [TBL] [Abstract][Full Text] [Related]
28. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels. Bays HE; Maki KC; Doyle RT; Stein E Postgrad Med; 2009 Sep; 121(5):145-50. PubMed ID: 19820283 [TBL] [Abstract][Full Text] [Related]
29. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Brodie MJ; Rosenfeld WE; Vazquez B; Sachdeo R; Perdomo C; Mann A; Arroyo S Epilepsia; 2009 Aug; 50(8):1899-909. PubMed ID: 19490053 [TBL] [Abstract][Full Text] [Related]
30. Upper-extremity disability in essential tremor. Héroux ME; Parisi SL; Larocerie-Salgado J; Norman KE Arch Phys Med Rehabil; 2006 May; 87(5):661-70. PubMed ID: 16635629 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial. Chang AK; Bijur PE; Baccelieri A; Gallagher EJ Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935 [TBL] [Abstract][Full Text] [Related]
33. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Haas M; Delbello MP; Pandina G; Kushner S; Van Hove I; Augustyns I; Quiroz J; Kusumakar V Bipolar Disord; 2009 Nov; 11(7):687-700. PubMed ID: 19839994 [TBL] [Abstract][Full Text] [Related]
34. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. Peniston JH; Gould E Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907 [TBL] [Abstract][Full Text] [Related]
35. A clinical test for the alcohol sensitivity of essential tremor. Knudsen K; Lorenz D; Deuschl G Mov Disord; 2011 Oct; 26(12):2291-5. PubMed ID: 22021159 [TBL] [Abstract][Full Text] [Related]
36. Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined Biomechanical Patterns - A New Future. Samotus O; Rahimi F; Lee J; Jog M PLoS One; 2016; 11(4):e0153739. PubMed ID: 27101283 [TBL] [Abstract][Full Text] [Related]
37. Effects of zonisamide on c-Fos expression under conditions of tacrine-induced tremulous jaw movements in rats: a potential mechanism underlying its anti-parkinsonian tremor effect. Miwa H; Kubo T; Suzuki A; Kondo T Parkinsonism Relat Disord; 2009 Jan; 15(1):30-5. PubMed ID: 18693129 [TBL] [Abstract][Full Text] [Related]
38. Effects of zonisamide on isolated head tremor. Song IU; Kim JS; Lee SB; Ryu SY; An JY; Kim HT; Kim YI; Lee KS Eur J Neurol; 2008 Nov; 15(11):1212-5. PubMed ID: 18754763 [TBL] [Abstract][Full Text] [Related]
39. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Frucht SJ; Bordelon Y; Houghton WH; Reardan D Mov Disord; 2005 Oct; 20(10):1330-7. PubMed ID: 15986420 [TBL] [Abstract][Full Text] [Related]
40. Stimulation of the motor cortex for disabling essential tremor. Lyons KE; Wilkinson SB; Pahwa R Clin Neurol Neurosurg; 2006 Sep; 108(6):564-7. PubMed ID: 16473460 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]